17 Sep 2020
CLN-081 (TAS6417; Pan-mutation–selective EGFR tyrosine kinase inhibitor) – Taiho/ Cullinan Pearl – subsidiary of Cullinan Oncology
Response characteristics | N=17 |
Best response | |
Progressive disease (PD), n (%) | 0 (0%) |
Stable disease (SD), n (%) | 11 (65%) |
Partial response (PR), n (%) | 6* (35%) |
Complete response (CR), n (%) | 0 (0%) |
Confirmed response, n | 2 |
Unconfirmed response, n | 1 |
Pending confirmation, n | 3* |
*one additional PR achieved after 01 Sep data cut |
CI Scientists Remarks:
– Dr. Kowndinya, CI Scientists
info@ciscientists.com
For a subscription, please provide your email id